Amplo Biotechnology Announces Three Presentations at the European Society of Gene and Cell Therapy 31st Annual Congress
SAN DIEGO, Oct. 17, 2024 /PRNewswire/ -- Amplo Biotechnology, a biotechnology company developing genetic medicines for the treatment of neuromuscular diseases, announced the presentation of three posters at the European Society of Gene and Cell Therapy (ESGCT) 31st Annual Congress, taking place from October 22-25, 2024, in Rome, Italy. Amplo will feature three poster presentations detailing its platform approach...
Telix Q3 2024 Business Update – Quarterly Revenue Exceeds AU$200M
MELBOURNE, Australia, Oct. 17, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on its revenue and operational performance for the quarter ended 30 September 2024 (Q3 2024). Revenue update, full year guidance reaffirmed Unaudited total revenue of approximately US$135 million (AU$201 million), primarily generated...
KIND Announces Late-Breaking Abstract Accepted for Presentation on AND017 Clinical Trials to Treat Anemia in Chronic Kidney Disease (CKD) at ASN – Kidney Week 2024
SAN FRANCISCO, Oct. 17, 2024 /PRNewswire/ -- Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC"), a clinical-stage biopharmaceutical company focused on developing innovative medicines to treat hematological diseases and cancers, today announced that the late-breaking abstract on the AND017 Phase 2 clinical trial for treatment of anemia in dialysis-dependent chronic kidney disease (DD-CKD) was accepted to present...
Cambrex Opens New Stability Storage Facility in Durham, North Carolina
EAST RUTHERFORD, N.J., Oct. 17, 2024 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced that their stability storage business, Q1 Scientific, has opened a new cGMP facility in Durham, North Carolina, expanding its capacity for environmentally controlled stability storage services to the pharmaceutical, medical device...
CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
Temporary marketing authorization is based on statistically significant and clinically meaningful results from the phase-III PROTECT trial ST. GALLEN, Switzerland and SAN DIEGO, Oct. 17, 2024 /PRNewswire/ -- CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that Swissmedic has granted temporary marketing authorization for FILSPARI for the treatment of adults with primary...
Bio X Cell Announces Board of Director Appointments
A Leading Producer of Monoclonal Antibodies LEBANON, N.H., Oct. 17, 2024 /PRNewswire/ -- Bio X Cell, LLC ("BXC" or the "Company"), the world's leading producer of monoclonal antibodies for pre-clinical in vivo research applications, is pleased to announce the appointments of Alan Hirzel and Kevin Ballinger to its Board of Directors. "We...
IND Application for a Phase Ⅲ Clinical Study of KN026 Combined with Albumin-bound Docetaxel as Neoadjuvant Treatment for Breast Cancer was Approved
SUZHOU, China, Oct. 17, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966 HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (stock code: 1093.HK) jointly announced that an application for a phase III clinical study (Study ID: KN026-004) of the anti-HER2 bispecific antibody KN026 combined with albumin-bound Docetaxel HB1801 has been approved by the Center for Drug Evaluation (CDE) of the National...
Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Ulcerative Colitis Met Primary Endpoint
SAN FRANCISCO and SUZHOU, China, Oct. 17, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that primary endpoint of 12-week induction period was met in a multicenter, randomized, double-blind, placebo-controlled phase 2 clinical study...
Presagen’s AI fertility product Life Whisperer acquired by Astec
ADELAIDE, Australia, Oct. 17, 2024 /PRNewswire/ -- Astec, a global manufacturer of medical equipment for assisted reproduction, has acquired Presagen's fertility product Life Whisperer, a non-invasive and rapid embryo and egg (oocyte) assessment tool designed to improve pregnancy outcomes for IVF patients. Life Whisperer comprises three AI algorithms. Life Whisperer Viability assesses images of embryos to determine the likelihood...
Mars announces new leadership for its Veterinary Health and Science & Diagnostics businesses
Nefertiti Greene announced as Global President of Mars Veterinary Health Katie Devine joining to lead Mars Science & Diagnostics Devine brings over 25 years' experience in consumer health and pharma Mars has been a global leader in pet care for almost 90 years, now spanning veterinary care, nutrition, veterinary diagnostics, DNA testing and platforms BRUSSELS, Oct. 16, 2024...
